CD8A and neoplasm: Compared to control mice tumor growth was delayed in mice which received DC-GP33 i.p. or i.v. This indicates that peptide-loaded DC activated CD8+ T cells, irrespective of the immunization route (confirming data from Fong et al [8]), but that only the i.c. route led to tumor rejection, either by licensing effector T cells to migrate into the skin efficiently and/or due to an enhanced expansion effector T cells.